Antibody Information

General Information of This Antibody (ID: ANTI0EZGCL)
Antibody Name
A humanized anti-SLC44A4 IgG2 mAb
Antigen Name
CTL4
  Antigen Info 
Click to Show/Hide the Sequence Information of This Antibody
Heavy Chain Sequence
MEFGLTWVFLVALLRGVQCQVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAP
GKGLEWVAVMSYDGSKKFYTDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGG
DYVRYHYYGMDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPV
TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKT
VERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWY
VDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISK
TKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPML
DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
    Click to Show/Hide
Heavy Chain Varible Domain
MEFGLTWVFLVALLRGVQCQVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAP
GKGLEWVAVMSYDGSKKFYTDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGG
DYVRYHYYGMDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPV
TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKT
VERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWY
VDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISK
TKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPML
DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
    Click to Show/Hide
Light Chain Sequence
MDMRVPAQLLGLLLLWLPDTRCDIQMTQSPSTLSASIGDRVTITCRASQGISYYLAWYQQ
KPGKIPKLLIYDTSSLQSGVPSRFSGSRSGTDLSLTISSLQPEDVATYYCQRYDSAPLTF
GGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGN
SQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
    Click to Show/Hide
Light Chain Varible Domain
MDMRVPAQLLGLLLLWLPDTRCDIQMTQSPSTLSASIGDRVTITCRASQGISYYLAWYQQ
KPGKIPKLLIYDTSSLQSGVPSRFSGSRSGTDLSLTISSLQPEDVATYYCQRYDSAPLTF
GGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGN
SQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
    Click to Show/Hide
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
ASG-5ME [Phase 1 (discontinued)]
 ADC Info 
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Patients Enrolled
Inclusion: Metastatic pancreatic adenocarcinoma or AGS-5+ gastric/GEJ adenocarcinoma (measurable disease &ge;10-15 mm), ECOG 0-1; untreated or &le;1 prior systemic therapy (2/4-week washout). Exclusion: CNS metastases, active malignancy (<3y remission), recent cardiac/CV events (NYHA III-IV), or untreated major organ dysfunction.
Administration Dosage
0.3-3.0 mg/kg IV on Days 1, 8, and 15 of 28-day cycles
Related Clinical Trial
NCT Number NCT01166490  Clinical Status PHASE1
Clinical Description
A Phase 1, Open-Label, Dose Escalation Study of ASG-5ME in Patients With Pancreatic or Gastric Adenocarcinoma
Primary Endpoint
Safety analysis includes incidence of adverse events and lab abnormalities (assessed until 1 month post-treatment), ASG-5ME/metabolite blood concentrations, and antitherapeutic antibody development.
Other Endpoint
Efficacy measures involve best clinical response (assessed every 2 months), overall survival, progression-free survival (monthly until death/study closure), and pharmacokinetic monitoring of ASG-5ME.
Experiment 2 Reporting the Activity Date of This ADC [2]
Patients Enrolled
Inclusion: Castration-resistant prostate cancer (progression post-standard therapy, no effective therapy, or patient declines), testosterone &le;50 ng/dL, ECOG 0-1, life expectancy >6 months, adequate hematologic/renal/hepatic function, stable LHRH/GnRH therapy, prior docetaxel allowed only if refractory/intolerant. Exclusion: CNS metastases, active malignancy (<3-year remission), significant cardiac disease, recent chemo/radiation/anti-androgens, neuropathy &ge;grade 2, major surgery/infection, HIV/HepB/HepC positivity, recent thromboembolic events.

   Click to Show/Hide
Related Clinical Trial
NCT Number NCT01228760  Clinical Status PHASE1
Clinical Description
A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of ASG-5ME Monotherapy in Subjects With Castration-Resistant Prostate Cancer (CRPC)
Primary Endpoint
Safety is evaluated through adverse events, lab tests (hematology, biochemistry), and vital signs during the 12-week treatment and 4-week follow-up. Pharmacokinetics of ASG-5ME is analyzed via blood samples (Cycle 1 & 4, pre-dose Cycles 2 & 3, and periodically thereafter if treatment continues).
Other Endpoint
Efficacy measures include anti-ASG-5ME antibody formation, tumor response (every 12 weeks), PSA levels, bone scans, circulating tumor cells, and cytokeratin-18 levels (assessed periodically during treatment).
References
Ref 1 A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma
Ref 2 A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer